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Background: It is uncertain whether lung-protective mechanical ventilation using low tidal volumes should be used
in all critically ill patients, irrespective of the presence of the acute respiratory distress syndrome (ARDS). A low tidal
volume strategy includes use of higher respiratory rates, which could be associated with increased sedation needs,
a higher incidence of delirium, and an increased risk of patient-ventilator asynchrony and ICU-acquired weakness.
Another alleged side-effect of low tidal volume ventilation is the risk of atelectasis. All of these could offset the
beneficial effects of low tidal volume ventilation as found in patients with ARDS.
Methods/Design: PReVENT is a national multicenter randomized controlled trial in invasively ventilated ICU patients
without ARDS with an anticipated duration of ventilation of longer than 24 hours in 5 ICUs in The Netherlands.
Consecutive patients are randomly assigned to a low tidal volume strategy using tidal volumes from 4 to 6 ml/kg
predicted body weight (PBW) or a high tidal volume ventilation strategy using tidal volumes from 8 to 10 ml/kg
PBW. The primary endpoint is the number of ventilator-free days and alive at day 28. Secondary endpoints include ICU
and hospital length of stay (LOS), ICU and hospital mortality, the incidence of pulmonary complications, including ARDS,
pneumonia, atelectasis, and pneumothorax, the cumulative use and duration of sedatives and neuromuscular blocking
agents, incidence of ICU delirium, and the need for decreasing of instrumental dead space.
Discussion: PReVENT is the first randomized controlled trial comparing a low tidal volume strategy with a high tidal
volume strategy, in patients without ARDS at onset of ventilation, that recruits a sufficient number of patients to test
the hypothesis that a low tidal volume strategy benefits patients without ARDS with regard to a clinically relevant
endpoint.
Trial registration: The trial is registered at www.clinicaltrials.gov under reference number NCT02153294 on 23
May 2014.
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Mechanical ventilation is generally seen as an invasive but
foremost safe supportive strategy in critically ill patients.
However, there is unequivocal and increasing evidence
from both experimental and clinical studies that ventilation
has a strong potential to aggravate, or even initiate injury to
lungs [1, 2] and respiratory muscles [3, 4]. Indeed, mechan-
ical ventilation may result in a ventilation pattern of ventral
overstretching and dorsal collapse of lung tissue, which
both play a role in development of so-called ‘ventilator-
induced lung injury’ (VILI). Mechanical ventilation is
also associated with respiratory muscle disuse and mis-
use, with concomitant atrophy of diaphragmatic myofi-
bers that plays a role in development of so-called
‘ventilator-induced diaphragm dysfunction’ (VIDD) [5].
The harmful effects of the traditional use of high tidal
volumes were not recognized until 2000 when the benefi-
cial effects of ventilation using a low tidal volume strategy
(6 ml/kg predicted body weight, PBW) in patients with the
acute respiratory distress syndrome (ARDS) were estab-
lished in the landmark NHLBI ARDS Network trial [6].
Some clinicians and investigators were reluctant to accept
these findings, but subsequent trials and a meta-analysis
convincingly confirmed the reduction in mortality by
using these lung-protective ventilator settings in patients
with ARDS [7]. Currently, lung-protective ventilation with
low tidal volumes is considered standard of care for pa-
tients with ARDS [8–10]. It is uncertain, however,
whether we should use a low tidal volume strategy in
all ICU patients: that is irrespective of the presence of
ARDS. While the results of a recent meta-analysis sug-
gests that tidal volume reduction also benefits patients
without ARDS [11], we should realize that the meta-
analyzed studies all had methodological shortcomings
and the majority of them focused on ventilation during
general anesthesia for surgery, which cannot be simply
generalized to other clinical situations like ventilation
of critically ill patients in the ICU setting.
Numerous arguments against indiscriminate use of low
tidal volume strategies have been raised. One argument is
that this strategy necessitates higher respiratory rates,
which could increase sedation needs [12], risk of ICU de-
lirium [13] or ICU-acquired weakness [14]. Other argu-
ments against unselective use of lower tidal volumes are
that it could promote collapse of lung tissue [15], and in-
creases the risk of patient-ventilator asynchrony [16, 17].
In addition, the increased efforts of patients on spontan-
eous ventilation using lower tidal volumes could induce
more so-called pendelluft, thereby actually increasing the
risk of lung injury [18]. Finally, another alleged side-effect
of higher respiratory rates is patient fatigue, although there
are no studies that support this fear.
The abovementioned suggested side-effects of low tidal
volume ventilation strategies could offset its potentialbeneficial effects, especially in patients without ARDS in
whom the benefits of using low tidal volumes could be less
than in those with ARDS. Consequently, lung-protective
ventilation using low tidal volumes is not yet recommended
in guidelines for ventilation of patients without ARDS,
resulting in remarkable and unwanted practice variation
[19, 20]. The ICU community explicitly requests a well-
powered trial comparing ventilation with low tidal volumes
to ventilation with high tidal volumes in patients without
ARDS [2, 11, 21, 22], a trial that should use patient-relevant
and objective outcomes, including duration of ventilation
and ICU and hospital length of stay (LOS).
The objective of the present trial, therefore, is to de-
termine whether ventilation with tidal volumes from 6
down to 4 ml/kg PBW, as compared to ventilation
with tidal volumes from 8 up to 10 ml/kg PBW reduces
duration of mechanical ventilation in ICU patients
without ARDS at onset of ventilation. Specifically, we
hypothesize that ventilation with low tidal volumes in-




The PReVENT (PRotective VENTilation in patients with-
out ARDS at start of ventilation) trial is an investigator-
initiated, national, multicenter, parallel randomized
controlled two-arm trial in intubated and ventilated
ICU patients not suffering from ARDS at onset of ventila-
tion. The PReVENT trial will be conducted according to
the principles of the Declaration of Helsinki as stated in
the current version of Fortaleza, Brazil, 2013 [23] and
in accordance with the Medical Research Involving Hu-
man Subjects Act (WMO). The Institutional Review
Board of the Academic Medical Center, Amsterdam,
The Netherlands, approved the trial protocol under refer-
ence number 2014_075#B2014424. The trial is registered
at www.clinicaltrials.gov (NCT02153294). Patients will be
provisionally included under a strategy of deferred consent
(see below).
CONSORT diagram
The Consolidated Standards of Reporting Trials (CON-
SORT) [24] diagram of PReVENT is presented in Fig. 1.
Consecutive patients admitted to one of the participating
ICUs who need invasive ventilation are screened. Demo-
graphic data are registered regardless of meeting enroll-
ment criteria. If excluded from participation, the reason(s)
for exclusion are registered.
Setting
PReVENT is performed in the ICUs of five centers in The
Netherlands: three university centers (Leiden University
Medical Center in Leiden, VU Medical Center in
Fig. 1 Consolidated Standards of Reporting Trials (CONSORT) diagram. PBW = predicted body weight
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and two teaching hospitals (Gelre Ziekenhuizen in
Apeldoorn and Tergooi in Hilversum).
Study population
Intubated and ventilated ICU patients are eligible for par-
ticipation if the need of ventilator support for longer than
24 hours is expected. Notably, patients who already re-
ceived ventilation before ICU admission: for example, in
the emergency room or in the operation room, are also
eligible, but need to be included within 1 hour of ventila-
tion in the ICU. Patients suspected of having ARDS at
start of ventilation, according to the Berlin definition [25],
must be excluded from participation. The PReVENT trial
accepts patients with a PaO2/FiO2 between 200 and 300
mmHg, but excludes patients with a PaO2/FiO2 < 200
mmHg within the first hour of ventilation unless it is likely
that fluid overload or cardiac failure are the cause of hyp-
oxia. Non-adult patients (age < 18 years) are excluded, asare patients previously randomized in PReVENT or par-
ticipating in other interventional trials, any session of ven-
tilation longer than 12 hours directly preceding current
ICU admission, pregnant patients, patients with increased
and uncontrollable intracranial pressure (of ≥ 18 mmHg),
patients suffering from GOLD classification III or IV
chronic obstructive pulmonary disease (COPD), with
status asthmaticus or premorbid restrictive pulmonary
disease (evidence of chronic interstitial infiltration on
previous chest radiographs), also patients with new
proven pulmonary thrombo-embolism or any previous
pneumectomy or lobectomy. Informed consent will be
obtained from all participants or a legal representative
in case the former is impossible.
Randomization and blinding
Randomization will be performed using a dedicated,
password protected, SSL-encrypted website with ALEA®
software (TenALEA consortium, Amsterdam, The
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only per ICU and per intubation location (that is intubated
in the ICU or before ICU admittance in the emergency
room or operation room). When, after randomization,
consent is rejected, the patient is excluded. Due to the
nature of the intervention, blinding is not possible.
The ventilation strategies to be compared
In both arms the size of tidal volumes is titrated on the
PBW, which is calculated according to a previously used
formula [6]:
50 þ 0:91 x centimeters of height – 152:4ð Þ for male; and
45:5 þ 0:91 x centimeters of height – 152:4ð Þ for females
Patients randomized to the ‘low tidal volume’-arm start
with a tidal volume of 6 ml/kg PBW. The tidal volume size
is decreased in steps of 1 ml/kg PBW per hour, to a
minimum of 4 ml/kg PBW, unless the patient suffers
from severe dyspnea (identified by increased respiratory
rate > 35 breaths per minute accompanied by increas-
ing levels of discomfort with or without need for more
sedation) or unacceptable acidosis (Table 1). The fol-
lowing actions could be taken to prevent respiratory
acidosis: increasing respiratory rate, removal of the heat
and moisture exchanger and decreasing instrumental
dead space by shortening ventilation tubing, to limit
dead space ventilation. Patients randomized to the low
tidal volume arm may need very little support when the
ventilator is switched to pressure support ventilation,
but a minimum of 5 cmH2O should be used. In case
the resulting tidal volume exceeds 6 ml/kg PBW this
must be accepted (that is this is neither a reason to use
(more) sedation and/or muscle relaxants, nor to switch
to volume-controlled ventilation) (see weaning).
Patients randomized to the ‘high tidal volume’-arm start
with a tidal volume of 10 ml/kg PBW. With volume-
controlled ventilation the plateau pressure should not
exceed 25 cm H2O [2]. Only if the plateau pressure ex-
ceeds 25 cmH2O the tidal volume is decreased in steps
of 1 ml/kg PBW per hour, to a minimum of 8 ml/kg
PBW (Table 1). Patients randomized to the high tidal
volume arm generally need more support when the
ventilator is switched to pressure support ventilation,
but the maximal airway pressure should never exceed
25 cmH2O [2]. In case the resulting tidal volume remains
below 10 ml/kg PBW this is accepted (that is this is
neither a reason to use (more) sedation and/or muscle
relaxants, nor to switch the ventilator to volume-
controlled ventilation) (see weaning).
Other ventilator settings
The allowed ventilation modes are volume-controlled ven-
tilation and pressure support ventilation. The inspiration-
to-expiration ratio with volume-controlled ventilation is1:2. With volume-controlled ventilation the inspiration
time and pause are set at 25 % and 10 % respectively. With
pressure support ventilation the highest possible pressure
rise is chosen, and cycling off is set at 25 %. The inspired
oxygen fraction is 0.21 or higher to maintain oxygen satur-
ation 90 to 92 % and/or PaO2 > 7.3 to 10.7 kPa (55 to 80
mmHg). The respiratory rate is adjusted to maintain a
blood pH of 7.25 to 7.45. In case of metabolic acidosis or -
alkalosis, a lower or higher than normal PaCO2 can be ac-
cepted, left to the discretion of the attending physician.
The lowest level of positive end-expiratory pressure
(PEEP) is 5 cmH2O; allowed FiO2-PEEP-combinations are
provided in Table 1. Recruitment maneuvers are allowed,
when deemed necessary, left to the discretion of the at-
tending physician.Weaning from ventilation
Daily assessment of the ability to breathe with pressure
support ventilation is required as soon as FiO2 ≤ 0.4 or
when the PEEP level and FiO2 level are lower than the
day before. In addition, the ventilator can be switched to
pressure support ventilation at any moment the attend-
ing nurse or physician considers the patient is awake
enough to breathe with pressure support ventilation. As-
sessment of the ability to breathe with pressure support
is also required in case patient-ventilator asynchrony is
noticed (that is ineffective breathing; double triggering,
use of accessory respiratory muscles).
A patient is assumed to be ready for extubation when
the following criteria are met for at least 30 minutes, the
final decision for extubation is made by the attending
physician: a patient is responsive and cooperative, has an
adequate cough reflex, PaO2/FiO2 of > 200 mmHg with
FiO2 ≤ 40 % and a respiratory rate of 8 to 30/minute with
no signs of respiratory distress (that is marked accessory
muscle use, abdominal paradox, diaphoresis, marked
dyspnea), the pressure support level is < 7 cmH2O (lower
tidal volume arm) or < 12 cmH2O (higher tidal volume
arm) with a temperature of > 36.0 °C and < 38.5 °C and is
hemodynamically stable (systolic blood pressure 80 to 160
mmHg and heart rate 40 to 130/minute) with no uncon-
trolled arrhythmia.
In the high tidal volume arm physicians and nurses
may lower the pressure support level first (that is before
extubation), to see whether patients can ventilate at the
lowest support level. This is not mandatory, though, as
extubation is also allowed with higher pressures. For
this, the pressure support level is lowered step-wise with
steps of 2 to 5 cmH2O per hour to < 7 cmH2O. If this is
not tolerated according to the conditions mentioned
above, the pressure support level is set back to maintain
a tidal volume as per randomization and the patient is
assessed for extubation the following shift.
Table 1 Ventilator settings with the two ventilation strategies
Lower tidal volume ventilation Higher tidal volume ventilation
Ventilator mode Assisted MV = volume- controlled Assisted MV = volume-controlled
Spontaneous MV = pressure support Spontaneous MV = pressure support
Target tidal volume 4 ml/kg PBW 10 ml/kg PBW
Allowable tidal volume in case of high pressures (in the high
tidal group) or severe dyspnea (in the low tidal group)
6 ml/kg PBWa 8 ml/kg PBWa
Allowable ventilator rate setting needed to achieve normal pH
(7.25 to 7.45)
6 to 35 breaths/minute; typically higher
than with an higher tidal volume
6 to 35 breaths/minute; typically lower
than with a lower tidal volume
Inspiration-to-expiration ratio 1:2 1:2
PaO2 or SpO2-targets 7.3 to 10.7 kPa (55 to 80 mmHg), or 90
to 92 %
7.3 to 10.7 kPa (55 to 80 mmHg), or 90
to 92 %
Allowable combinations of FiO2 and PEEP 0.21 and 5 cmH2O 0.21 and 5 cmH2O
0.30 and 5 cmH2O 0.30 and 5 cmH2O
0.40 and 5 cmH2O 0.40 and 5 cmH2O
0.40 and 8 cmH2O 0.40 and 8 cmH2O
0.50 and 8 cmH2O 0.50 and 8 cmH2O
0.50 and 10 cmH2O 0.50 and 10 cmH2O
0.60 and 10 cmH2O 0.60 and 10 cmH2O
Daily assessment of the ability to breathe with pressure support Required when FiO2 ≤ 0.4 or earlier Required when FiO2 ≤ 0.4 or earlier
Allowable tidal volume when ARDS develops 6 ml/kg PBW 6 ml/kg PBW
Allowable tidal volume when ARDS develops; in case of severe
dyspnea or unacceptable pH
8 ml/kg PBW 8 ml/kg PBW
Allowable combinations of FiO2 and PEEP (continued) 0.21 and 5 cmH2O 0.21 and 5 cmH2O
0.30 and 5 cmH2O 0.30 and 5 cmH2O
0.40 and 5 cmH2O 0.40 and 5 cmH2O
0.40 and 8 cmH2O 0.40 and 8 cmH2O
0.50 and 8 cmH2O 0.50 and 8 cmH2O
0.50 and 10 cmH2O 0.50 and 10 cmH2O
0.60 and 10 cmH2O 0.60 and 10 cmH2O
0.70 and 10 cmH2O 0.70 and 10 cmH2O
0.70 and 12 cmH2O 0.70 and 12 cmH2O
0.70 and 14 cmH2O 0.70 and 14 cmH2O
0.80 and 14 cmH2O 0.80 and 14 cmH2O
0.90 and 14 cmH2O 0.90 and 14 cmH2O
0.90 and 16 cmH2O 0.90 and 16 cmH2O
0.90 and 18 cmH2O 0.90 and 18 cmH2O
1 and 18 cmH2O 1 and 18 cmH2O
1 and 20 cmH2O 1 and 20 cmH2O
1 and 22 cmH2O 1 and 22 cmH2O
1 and 24 cmH2O 1 and 24 cmH2O
awith pressure support tidal volumes could be higher than targeted with the lowest possible pressure support level, or lower than targeted with the highest
allowed maximum airway pressure - this is accepted and never a reason for use of (more) sedation, paralytic agents, and/or switch to a controlled mode
of ventilation
ARDS acute respiratory distress syndrome, FiO2 O2–fraction of inspired air, MV mechanical ventilation, PBW predicted body weight, PEEP positive end-expiratory
pressure, SpO2 peripheral O2 saturation
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sequently requires additional ventilation within 28 days
after randomization, the same tidal volume protocol is
used. Non-invasive ventilation is allowed, but an attempt
should be made to have comparable tidal volumes as
with invasive ventilation, as per randomization.
Tracheostomy
Early tracheostomy has no advantage over late trache-
ostomy [26]. Therefore, tracheostomy is only to be per-
formed on strict indications and preferably not earlier
than 10 days after intubation. Strict indications for
tracheostomy are failure to intubate, expected duration
of ventilation > 14 days, Glasgow Coma Score < 7 and/
or inadequate swallow or cough reflex with retention of
sputum, severe ICU-acquired weakness, prolonged or
unsuccessful weaning and repeated respiratory failure
after tracheal extubation.
Standard procedures
Sedation follows the local guidelines in each participat-
ing hospital. In general, these guidelines favor the use of
analgo-sedation over hypno-sedation, use of bolus over
continuous infusion of sedating agents, and the use of
sedation scores. Nurses determine the level of sedation
at least three times per day. The adequacy of sedation in
each patient is evaluated using a Richmond Agitation
Sedation Scale (RASS) [27, 28]; a RASS score of −2 to 0
is considered adequate sedation. As stated above, sedation
adjustments should never be done to allow a lower or
higher tidal volume. The goals of sedation are to reduce
agitation, stress and fear; to reduce oxygen consumption
(heart rate, blood pressure and minute volume are mea-
sured continuously); and to reduce physical resistance to,
and fear of, daily care and medical examination. Patient
comfort is the primary goal. Level of pain is determined
using Numeric Rating Scale (NRS), Visual Analog Scale
(VAS), Critical Care Pain Observation Tool (CCPOT) or
Behavioral Pain Scale (BPS).
To prevent nosocomial infections, selective oropharyn-
geal decontamination (SOD) or selective decontamin-
ation of the digestive tract (SDD) is performed in all
patients who are expected to need ventilation for longer
than 48 hours, and/or are expected to stay in ICU for
longer than 72 hours [29].
Thrombosis prophylaxis is indicated for all patients
who are not treated with anticoagulants: for example,
for therapeutic reasons or systemic prophylaxis because
of an implanted device or extra-corporeal circulation like
veno-venous hemofiltration. Thrombosis prophylaxis
will be given according to local guidelines.
A fluid balance targeted at normovolemia and a diuresis
of ≥ 0.5 ml/kg/hour should be maintained. Crystalloid
infusions are preferred over colloid infusions.A hypo-caloric, protein-rich diet (1.2 to 1.7 g/kg body-
weight/24 hours) is started as soon as possible after ICU
admission. Enteral nutrition with a feeding gastric tube
is preferred over intravenous feeding. If stomach reten-
tion occurs a duodenal tube can be used if administra-
tion of prokinetics is not sufficient, according to local
guidelines. When optimal protein intake cannot be
reached within 4 days, additional parenteral nutrition
can be started.
Follow-up
On ICU admission and within the first 24 hours, demo-
graphic and baseline data, as well as data on disease se-
verity are collected. Data collection includes: gender,
age, height, weight, reason for ICU admission, reason for
ventilation, cause of respiratory failure, the Acute Physi-
ology and Chronic Health Evaluation II (APACHE II)
score and the Simplified Acute Physiology Score II
(SAPS II).
Data on standard of care and clinical outcome vari-
ables (described below) are collected on a daily basis
every day until day 28, discharge of the ICU or death,
whichever comes first. Data on duration of ventilation,
length of stay in ICU and hospital, location of the pa-
tient (in ICU, hospital, other facility, or home) and life
status (alive or deceased) are assessed on days 28 and
90.
The following variables are collected daily: respiratory
status; intubation status (if extubated: time of extuba-
tion/if re-intubated: time of re-intubations) tracheos-
tomy status (if tracheostomized: time of tracheotomy),
invasiveness of ventilation (invasive, non-invasive, or
intermittent ventilation via tracheostomy), need for
decreasing instrumental dead space; development of pul-
monary complications (moderate or severe ARDS, pneu-
monia, atelectasis and pneumothorax); cumulative use
and duration of sedatives and neuromuscular blocking
agents; sedation score using the RASS [27, 28]; level of
pain (NRS or VAS or CCPOT or BPS); delirium score with
the Confusion Assessment Method for ICU (CAM-ICU)
score [30, 31]; presence of ICU-acquired weakness
using Medical Research Council (MRC) score [32] or
Grip Strength Assessment [33].
The following mechanical ventilation parameters
are collected within 1 hour before and 1 hour after
randomization, and every day at a fixed time point until
cessation of ventilation: tidal volume in ml and ml/kg
PBW, respiratory rate, level of PEEP, peak and plateau
pressures, or level of pressure support and maximal airway
pressure, inspiration to expiration ratio, inspired oxygen
fraction, minute volume, pulmonary compliance, Lung In-
jury Score (LIS: based on chest X-ray findings, PaO2/FiO2,
PEEP level and respiratory compliance) [34] and Oxygen-
ation Index [35].
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respiratory parameters and arterial blood gas analysis
(once daily), amount and type of infused products in-
cluding blood products and fluids (crystalloids and (arti-
ficial) colloids), cumulative fluid balance and Sequential
Organ Failure Assessment (SOFA) score [36].
Resource use parameters and unit prices are collected to
estimate health care costs from a health systems perspec-
tive and include costs of ventilation, costs of stay in ICU,
costs of stay in hospital, costs of cumulative use of seda-
tives, costs of neuromuscular blocking agents, costs of use
of tracheostomies and costs of ventilator-associated pneu-
monia (VAP).
Study endpoints
The primary endpoint is the number of ventilator-free
days and alive at day 28, defined as the number of days
from day 1 to day 28 the patient is alive and breathes with-
out invasive assistance of the mechanical ventilator for at
least 24 consecutive hours. To calculate this endpoint all
relevant data will be taken into account and collected,
including repeated re-intubation and -extubation.
Secondary endpoints are subdivided into clinical out-
come variables and health-economic outcome variables.
Clinical outcome variables include: ICU- and hospital
length of stay (LOS), ICU-, hospital-, and 90-day mortal-
ity, development of ARDS, VAP, development of atelec-
tasis and presence of pneumothorax and cumulative use
and duration of use of sedatives, cumulative use and
duration of use of neuromuscular blocking agents (other
than used for intubation), and ICU-acquired weakness
and delirium. Health-economic variables include incre-
mental cost per ICU-day avoided and incremental cost
per mechanical ventilation-day avoided.
Statistical considerations
We will include a total of 952 patients. The required
sample size is calculated using data from the recently
published meta-analysis [11] and a secondary analysis of
this meta-analysis using individual patient data from the
studies performed in ICU patients [37]. The sample size is
computed and based on the hypothesis that ventilation
with low tidal volumes is associated with a reduction of 1
day of ventilation. A sample size of 397 patients in each
group has 80 % statistical power to detect a difference of 1
ventilator-free day and alive at day 28 after ICU admission,
assuming that the common standard deviation is 5 using a
2 -group t-test with a 0.05 2-sided significance level. The
sample size is increased by 20 % to correct for dropouts
and those lost to follow-up meaning that each group will
contain 476 patients.
For this study we will include patients using a strategy
using deferred informed consent because we explicitly
want to randomize and start ventilation according torandomization within 1 hour after start of ventilation, or
within 1 hour after admission if ventilation was initiated
in the emergency room or the operation room. Never-
theless, written informed consent from the legal repre-
sentative will be requested as soon as possible thereafter,
and never later than 24 hours after randomization. If in-
formed consent is not obtained within those 24 hours,
or if a legal representative denies participation within
this time frame, the patient is excluded and data will no
longer be used, nor will this patient be counted for the
sample size of 476 inclusions in each group (that is the
provisionally included patient for whom informed con-
sent is not obtained within the time frame of 24 hours is
‘replaced’ by a new patient, until the total number of
476 patients in each arm is definitively included).
Statistical analysis
The primary outcome, the number of days alive and free
of ventilation at day 28, will be analyzed using Cox’s re-
gression. Possible imbalance between groups will be mod-
eled in the Cox model. P-values of 0.05 are used for
statistical significance. When appropriate, statistical uncer-
tainty will be expressed by the 95 % confidence levels. All
statistical analyses will be performed with the R language
and environment for statistical computing.
Continuous normally distributed variables will be
expressed by their mean and standard deviation or when
not normally distributed as medians and their interquar-
tile ranges. Categorical variables will be expressed as n
(%). To test groups Student’s t-test will be used, if con-
tinuous data is not normally distributed the Mann-
Whitney U-test will be used. Categorical variables will
be compared with the Chi-square test or Fisher’s exact
tests. Time dependent data will be analyzed using a pro-
portional hazard model adjusted for possible imbalances
of patients’ baseline characteristics. Analysis will be per-
formed with R statistics version 3.0.2 (R Foundation,
Vienna, Austria). Patient characteristics will be com-
pared and described by appropriate statistics.
The goal of the primary analysis is to quantify the effect
of ventilation using low tidal volumes versus ventilation
using high tidal volumes on the number of ventilator-free
days and alive at day 28. Statistical analysis will be based
on the intention-to-treat principle. We will also perform a
per-protocol analysis, comparing patients who received
lower tidal volumes and patients who received higher tidal
volumes. Other secondary analyses include: patients who
had pneumonia versus patients without pneumonia, and
patients with sepsis versus patients without sepsis.
Study organization
The steering committee is composed of the principal in-
vestigator, the coordinating investigator, the local investi-
gators in the participating ICUs, and six (inter)-national
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revisions of the study protocol. The coordinating investi-
gator is responsible for administrative management and
communication with the local investigators and provides
assistance to the participating clinical sites in trial manage-
ment, record keeping and data management. The coordin-
ating investigator helps in setting up local training in the
participating ICUs to ensure the study is conducted ac-
cording to the ICH-GCP guidelines, to guaranty integrity
of data collection and to ensure timely completion of the
case report forms. The local investigators provide struc-
tural and scientific leadership. They guarantee the integrity
of data collection and ensure timely completion of the
case report forms.
An independent monitor is installed to perform study
monitoring. Remote monitoring by means of queries on
the database will be done by a statistician and analyzed
by the monitor to signalize early aberrant patterns,
trends, issues with consistency or credibility and other
anomalies. On-site monitoring will comprise controlling
presence and completeness of the research dossier and
the informed consent forms, source data checks will be
performed in the files of 25 % of the patients. Each ICU
will be visited at least once every year.
An independent Data and Safety Monitoring Board
(DSMB) watches over the ethics of conducting the study
in accordance with the Declaration of Helsinki, monitors
safety parameters and the overall conduct of the study.
The DSMB is composed of five independent individuals
(Prof. Antonio Artigas Raventós, Prof. Thomas Bein, Prof.
Ognjen Gajic, Dr. Diederik Gommers and Prof. Herman
Wrigge). The DSMB will meet by conference calls. The
first meeting is scheduled after the first 150 patients.
Subsequent to this meeting the DSMB will meet every
6 months.
As this study compares two treatment strategies that are
used in standard care, no related serious adverse events
are expected. All unexpected adverse events will be re-
ported to the DSMB. Any report and/or advice of the
DSMB will be send to the sponsor of the study, the Aca-
demic Medical Center, Amsterdam, The Netherlands.
Should the sponsor decide not to fully implement advices
of the DSMB, the sponsor will send the advice to the
reviewing Institutional Review Board, including a note to
substantiate why (part of) the advice of the DSMB will not
be followed.
Discussion
PReVENT is the first randomized controlled trial that is
sufficiently powered to test the hypothesis that a ventila-
tion strategy using low tidal volumes, as compared to a
ventilation strategy using high tidal volumes, benefits pa-
tients without ARDS with regard to the clinically rele-
vant endpoint of duration of ventilation.It is increasingly becoming clear that ventilation per se
has the potential to initiate lung injury or ARDS, mainly
due to over-distension of (parts of ) the lung [2]. Since a
generally employable alternative treatment for ventila-
tion is not yet at our disposal, the prevention of over-
distension and lung injury should be the target. Earlier
clinical studies indicated that ventilation using low tidal
volumes could prevent development of lung injury by
avoiding excessive stretch, and that high tidal volumes
are more likely to cause damage in patients without
ARDS [22]. A sufficiently-powered randomized con-
trolled trial investigating the effects of low tidal volume
ventilation in patients without ARDS is presently lack-
ing. PReVENT follows an earlier randomized controlled
trial in The Netherlands [21] that was prematurely
stopped because of an unexpected benefit (that is reduc-
tion in development of new ARDS). In contrast to the
previous randomized controlled trial, PReVENT uses
duration of ventilation as primary endpoint. This end-
point is objective and foremost clinically relevant.
Namely, protracted use of ventilation is associated with
serious physiological and psychological sequelae. Compli-
cations associated with ventilation are well-known and in-
clude VAP and ICU-acquired weakness. Psychological
sequelae associated with protracted use of ventilation are
post-traumatic stress disorder [38–40], anxiety and de-
pression [41], delirium [30, 42] and cognitive deficits [43].
Also, from an economic perspective, any intervention that
shortens duration of ventilation and/or ICU length of stay
is highly relevant.
We anticipate PReVENT to be a highly feasible trial, as
the study procedures are straightforward, without difficult
or complex interventions. Furthermore, PReVENT uses a
deferred consent strategy to include patients rapidly in the
trial, and also those who are admitted during evenings or
nights when researchers are frequently not around to ask
for informed consent. This will create a study population
representative of the average ICU population. A lean study
protocol, not involving complex analyses and sampling of,
for example, blood or lung lavage fluid, will limit the
burden on daily activities.
PReVENT specifically prescribes a range of tidal vol-
umes for each group. We aim to ventilate patients with
tidal volumes of 4 ml/kg PBW or 10 ml/kg PBW, depend-
ing on randomization, but physicians and nurses are
allowed to change the tidal volumes following strict guide-
lines: in case of a too high respiratory rate (in the lower
tidal volume group), the tidal volume size can be increased
stepwise to 6 ml/kg PBW - in case of too high airway pres-
sures (in the higher tidal volume group), the tidal volume
size can be decreased stepwise to 8 ml/kg PBW. Experi-
ences with the study protocol suggest that the average
tidal volumes will be 5 and 9 ml/kg PBW [21]. Notably,
we aim for tidal volumes lower than 6 ml/kg PBW in the
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suggest more benefit from further reductions in tidal vol-
ume size in patients with ARDS [10, 44–47]. Certainly,
use of lower tidal volumes mandates use of higher respira-
tory rates to prevail adequate minute ventilation. Higher
respiratory rates are typically seen as uncomfortable and
maybe even unfeasible in non-sedated non-paralyzed
patients. However, neither observational studies [48]
nor the abovementioned randomized controlled trial in
The Netherlands [21] suggested this to be a realistic
problem. This was confirmed in a recently published
meta-analysis that showed no differences in sedation
needs between strategies using lower tidal volumes and
those using higher tidal volumes [37].
At present, the size of tidal volumes in patients without
ARDS is highly variable. For instance, two recent meta-
analyses show that 11 % of patients are ventilated with
tidal volumes of 4 to 6 ml/kg PBW and 53 % of patients
are ventilated with tidal volumes > 8 ml/kg PBW [37, 49].
Also, the proposed level of PEEP is that level that is used
as standard care in the participating hospitals, which is
usually 5 cmH2O. The study protocol, however, advises on
the best FiO2-PEEP-combinations [6].
From a physiological viewpoint one may argue that the
seemingly ‘one size fits all’ approach that is used in this
study does not allow individual titrations of tidal vol-
umes. Indeed, more sophisticated approximations of the
functional lung volume are possible: for example, by
driving pressures as recently reported to be possibly
more efficient in patients with ARDS [50]. It is highly
uncertain, though, whether a similar relationship be-
tween driving pressure and outcome exists in patients
without ARDS. Notably, the study protocol of PReVENT
allows individual titrations, as tidal volume size could be
adjusted depending on respiratory rate and airway
pressures.
A patient’s height is necessary for calculating the size
of tidal volumes to be used, as PBW is a function of pa-
tient’s height. Preferably we use height as reported in the
medical record of each individual patient. If absent, for
example, in patients who are acutely admitted from out-
side the hospital or when the medical record is not avail-
able, nurses and researchers must use tape measures.
Nevertheless, measuring height in supine patients with a
tape measure could result in height values slightly differ-
ent from those obtained by measuring height in a stand-
ing patient [51]. This bias cannot be avoided.
In PReVENT patients will be provisionally included
under a strategy of deferred consent. The reasons to
choose for such a strategy are twofold: first, many if not all
patients admitted for ventilation are incompetent to give
informed consent; second, obtaining informed consent
from a legal representative takes on average up to half
a day [52]. Both experimental [53] and clinical studies[54–56] clearly show ventilation-induced lung injury is
caused within hours. To keep the period of ‘uncon-
trolled’ ventilation as short as possible, using deferred
informed consent, we can randomize patients within 1
hour of start of ventilation, or within 1 hour after arrival
in the ICU.
Patients who present with ARDS according to the
Berlin definition [25] are excluded from participation in
PReVENT. In the first hour after intubation and start of
ventilation, usually shortly after admission to the ICU,
the medical history could be incomplete and the chest
X-ray reading could not yet be available, leaving the at-
tending physician only with the PaO2/FiO2 to exclude
ARDS. Post-intubation atelectasis, usually short-lasting,
cardiac failure and fluid overload, however, are the im-
portant causes for hypoxia in these patients. As patients
with other reasons than ARDS for hypoxia should not
be excluded from participation in PReVENT, we decided
the following: in case the medical history is incomplete
and the chest X-ray is not yet obtained, a PaO2/FiO2 be-
tween 200 and 300 mmHg is not a reason for excluding a
patient from participation - patients with a PaO2/FiO2 <
200 mmHg, however, are not accepted, unless hypoxia is
likely explained by cardiac failure or fluid overload. This
approach is pragmatic but may not be perfect: it is pos-
sible that a small proportion of patients are diagnosed
with ARDS in the following hours. Of course, then tidal
volumes must be lowered to 6 ml/kg PBW - these pa-
tients, however, do not leave the trial, as the primary ana-
lysis follows the intention-to-treat principle. It is also
possible that patients with a PaO2/FiO2 < 200 mmHg are
excluded while not having ARDS. Here we prefer safety,
and accept the risk of bias.
PReVENT knows several strengths. First, the study
protocol is pragmatic and easy to follow. The trial is
highly feasible, and inclusion of patients is not difficult.
Also, PReVENT will be performed in the ICUs of differ-
ent types of hospitals, increasing the generalizability of
its findings. Furthermore, early contamination with the
other ventilation strategy is prevented as much as pos-
sible by the rule that patients must be randomized to
one of the two arms of the study within an hour.
One important limitation of PReVENT is that blinding
is not possible due to the nature of the intervention,
which could induce bias. However, the weaning process,
which directly influences the primary outcome, stays
within the hands of the attending ICU physician and
nurse with no specific interest in PReVENT, and all ana-
lyses are performed in a blinded fashion. Second, sedation
practice could mask potential patient discomfort caused
by one or both ventilation strategies. However, it is
stressed to aim for similar sedation aims in both arms of
the trial. Third, when ventilation mode is switched from
controlled - to spontaneous ventilation, tidal volumes may
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In a previous randomized controlled trial we experienced
this to happen only within some hours after the switch;
thereafter, tidal volume size was less difficult [21]. As with
all multicenter studies, differences in care practice and
complications such as ICU-acquired infections amongst
the participating centers could be confounding factors.
Also, we chose to accept a heterogeneous group of pa-
tients alike in a preceding trial of critically ill patients test-
ing a similar intervention, and not to stratify for certain
conditions [21]. If subgroups are large enough, we could
decide to perform a post-hoc analysis.
In conclusion, PReVENT is the first national, investiga-
tor-initiated randomized controlled trial that is adequately
powered to test the hypothesis that a ventilation strategy
using low tidal volumes of 6 down to 4 ml/kg PBW bene-
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